Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

被引：81
|
作者：
Batocchi, AP
Rotondi, M
Caggiula, M
Frisullo, G
Odoardi, F
Nociti, V
Carella, C
Tonali, PA
Mirabella, M
机构：
[1] Catholic Univ, Neurol Inst, I-00168 Rome, Italy
[2] Univ Naples, F Magrassi Inst Endocrinol II, Dept Clin & Expt Med, I-80121 Naples, Italy
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2003年 / 139卷 / 1-2期
关键词：
leptin; cytokines; multiple sclerosis; interferon beta;
D O I：
10.1016/S0165-5728(03)00154-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after I year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：150 / 154
页数：5
相关论文
共 50 条
  • [31] Antibodies to interferon-beta in patients with multiple sclerosis: Detection and clinical effects
    Sadiq, SA
    Revesz, KJ
    Lassman, AB
    Miller, JR
    NEUROLOGY, 1996, 46 (02) : 1073 - 1073
  • [32] Thrombotic microangiopathy associated with interferon-beta treatment in patients with multiple sclerosis
    Baghbanian, Seyed Mohammad
    Moghadasi, Abdorreza Naser
    IRANIAN JOURNAL OF NEUROLOGY, 2018, 17 (02) : 89 - 90
  • [33] Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis
    Gilli, F
    Marnetto, F
    Caldano, M
    Sala, A
    Malucchi, S
    Di Sapio, A
    Capobianco, M
    Bertolotto, A
    JOURNAL OF NEUROIMMUNOLOGY, 2005, 158 (1-2) : 195 - 203
  • [34] Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
    Hyun, Jae-Won
    Kim, Gayoung
    Kim, Yeseul
    Kong, Byungsoo
    Joung, Aeran
    Park, Na Young
    Jang, Hyunmin
    Shin, Hyun-June
    Kim, Su-Hyun
    Ahn, Suk-Won
    Shin, Ha Young
    Huh, So-Young
    Kim, Woojun
    Park, Min Su
    Kim, Byung-Jo
    Kim, Byoung Joon
    Oh, Jeeyoung
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2018, 14 (02): : 186 - 190
  • [35] MicroRNA Dysregulation in Multiple Sclerosis: A Comparative Study in Treatment-Naive and Interferon-beta Treated Patients
    Waschbisch, Anne
    Schwab, Stefan
    Derfuss, Tobias
    NEUROLOGY, 2011, 76 (09) : A654 - A654
  • [36] Suggested limits for high and low neutralising antibody levels in interferon-beta treated multiple sclerosis patients
    Gibbs, E.
    Oger, J.
    MULTIPLE SCLEROSIS, 2006, 12 : S204 - S204
  • [37] The Effects of Disease Activity and Interferon-beta on Telomere Length and Telomerase Activity in Multiple Sclerosis
    Wakerley, Benjamin R.
    Nicholas, Richard S.
    Malik, Omar R.
    Altmann, Daniel M.
    NEUROLOGY, 2011, 76 (09) : A135 - A135
  • [38] Gender effects in the treatment of multiple sclerosis with interferon-beta
    Magyari, M.
    Koch-Henriksen, N.
    Laursen, B.
    Sorensen, P. S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 191 - 191
  • [39] Targets for the therapeutic action of interferon-beta in multiple sclerosis
    Hartung, HP
    Kieseier, BC
    ANNALS OF NEUROLOGY, 1996, 40 (06) : 825 - 826
  • [40] FDA OKAYS INTERFERON-BETA FOR MULTIPLE-SCLEROSIS
    THAYER, A
    CHEMICAL & ENGINEERING NEWS, 1993, 71 (31) : 5 - 6
12345